Today: 1 February 2026
Subscribe
Browse Category

NYSE:HIMS News 29 December 2025 - 31 December 2025

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NEW YORK, December 31, 2025, 05:39 ET — Premarket Shares of Hims & Hers Health Inc (HIMS) fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google The drift lower keeps attention on the telehealth group’s exposure…
31 December 2025
·······
Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

NEW YORK, December 29, 2025, 01:59 ET — Market closed. Hims & Hers Health Inc shares last closed down about 1% at $34.31 on Friday, extending a four-session slide as U.S. markets headed into the final trading days of the year. Investing The move matters now because year-end trading typically brings lighter volumes and sharper swings, leaving growth stocks sensitive…
29 December 2025
·····

Stock Market Today

  • Advantest Shares Surge 8.4% on Upgraded Guidance and Treasury Share Cancellation Plans
    February 1, 2026, 11:43 AM EST. Advantest Corporation (TSE:6857) stock jumped 8.4% after the company posted record nine-month results and raised its March 2026 full-year guidance to ¥1.07 trillion in net sales and ¥454 billion in operating income. The boost comes amid strong demand for AI-related semiconductor testers. The board is also considering cancelling treasury shares, which would reduce the equity base and potentially increase earnings per share. Despite the upbeat outlook, high valuation multiples and market cyclicality present risks. Investor sentiment remains vulnerable to any slowdown in tester demand, with fair value estimates for Advantest ranging widely between ¥8,300 and ¥19,200, reflecting divided investor views on its premium pricing and growth prospects in advanced semiconductors.
Go toTop